Centre for Pharmacoepidemiology, Karolinska Institutet (CPE-KI)

24/03/2010
02/06/2026
Institution
Educational Institution
Laboratory/Research/Testing facility
Not-for-profit
Download as PDF
Institution identification

Institution ID

47342

Institution full name and acronym

Centre for Pharmacoepidemiology, Karolinska Institutet (CPE-KI)

Institution countries

Sweden

Type of institution

Educational Institution
Laboratory/Research/Testing facility
Not-for-profit

Institution role

Researcher

Institution website

ENCePP partner

Yes
Institution description
The Centre for Pharmacoepidemiology (CPE) has over 20 years of experience working in a dynamic environment at the intersection of academia, healthcare, regulatory authorities and the pharmaceutical industry. CPE conducts research on drug safety, drug effectiveness and drug utilization and performs Post Authorisation Safety Studies (PASS) and Drug Utilization Studies (DUS) within the area of pharmacoepidemiology and real world evidence (RWE). A large part of the research is based on real world data from Swedish national registers at the National Board of Health and Welfare and Statistics Sweden. Data from quality registers and medical records are also included when relevant. As frequent participants and coordinators of large multinational projects, CPE has extensive experience in international collaboration, data sharing, and cross national data access legislation.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact details

Studies conducted by the institution

A Drug Utilization Study to Evaluate Indicators of Adherence to the Risk Minimization Measures for Ritlecitinib Using Electronic Healthcare Data in Denmark, France, and Sweden
A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures (RMMs) for Abrocitinib in the EU Using Electronic Healthcare Data (B7451085)
A multinational active safety surveillance study of crizotinib in Europe and the United States
A non-interventional study to examine patient characteristics and drug utilization patterns in migraine patients treated with prophylactic drugs in Nordic countries
A pharmacoepidemiological study to examine patient characteristics, drug utilization pattern and crude incidence rates of selected outcomes in new users of ticagrelor,clopidogrel and prasugrel in national Swedish registries.
A Population-based Cohort Study of Pregabalin to Characterize Pregnancy Outcomes
A population-based cohort study using an existing database to evaluate the association between latanoprost use and primary malignant ocular melanoma and facial cutaneous melanoma
A Population-based Study of the Safety of Gabapentin Use During Pregnancy
A post-marketing registry-based prospective cohort study of long-term safety of risankizumab in Denmark and Sweden
An Active Safety Surveillance Program To Monitor Selected Events In Patients With Long-Term Voriconazole Use
An Active Surveillance Study to Monitor the Real-World Long-term Safety of Somatrogon Among Paediatric Patients in Europe
An Active Surveillance Study to Monitor the Real-World Safety of Ritlecitinib Among Patients with Alopecia Areata in Denmark, France, and Sweden
An Active Surveillance Study to Monitor the Safety of Abrocitinib Among Real-World Patients with Atopic Dermatitis (AD) in the European Union (EU) (B7451084)
An Active Surveillance, Post-Authorization Safety Study to Characterize the Safety of Etrasimod in Patients with Ulcerative Colitis Using Real-World Data in the European Union (C5041046)
An observational cohort study to evaluate the risk of adverse pregnancy outcomes in patients treated with etanercept compared to those not treated with etanercept or other biologics using merged data from Sweden, Denmark and Finland
An Observational Postauthorization Safety Study To Describe The Safety Of Ustekinumab and Other Biologic Treatments in a Cohort of Patients With Ulcerative Colitis or Crohn’s Disease Using Compulsory Swedish Nationwide Healthcare Registers and the Independent Swedish National Quality Register for Inflammatory Bowel Disease (SWIBREG) (Stelara UC/CD PASS (SWIBREG))
Beyond Pooled – Part of the BEYOND study program (Benefit of NOACs study of non-valvular AF patients in nordic countries) (BEYOND Pooled (Denmark, Norway, Sweden))
CAncer Risk and INsulin analoGues (CARING) project
Cilostazol Drug Utilisation Study
Cohort Study of Long-term Safety of Upadacitinib for the Treatment of Ulcerative Colitis and Crohn’s Disease in a Real-world Setting in Europe
Cohort Study of Long-term Safety of Upadacitinib in the Treatment of Atopic Dermatitis in Denmark and Sweden
Cohort Study of the Incidence of Major Cardiovascular Events in New Adult Users of Lisdexamfetamine and Remote Adult Users of Other ADHD Treatments
Cohort Study of the Relative Incidence of Major Cardiovascular Events Among Patients Initiating Prucalopride Versus a Matched Comparator Cohort
Comparative Cohort Study of Long-term Safety Outcomes of Risankizumab Compared to Biologic Treatments for Ulcerative Colitis and Crohn’s Disease in a Real-world Setting in Sweden and Denmark
CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study
Denosumab Global Safety Assessment in Multiple Observational Databases (20090522)
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International, CONSIGN meta-analyses))
Drug Utilization Study Evaluating Additional Risk Minimisation Measures for Upadacitinib in the Treatment of Ulcerative Colitis in Europe
Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe
EPID Multiple Sclerosis Pregnancy study - Pregnancy outcomes in Multiple Sclerosis populations exposed and unexposed to interferon beta - a register-based study in the Nordic countries
Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions
MS700568_0004: Pregnancy outcomes in women exposed to oral cladribine: a multi-country cohort database study (CLEAR)
NN9535-4447 Epidemiological assessment of the risk for pancreatic cancer associated with the use of semaglutide in patients with type 2 diabetes- A cohort study based on Nordic registry data
Nordic Country Patient Registry for Romiplostim (NCPRR): Population-Based Prospective Annual Assessment of Safety of Romiplostim Treatment in Adult Patients with Chronic Idiopathic (Immune) Thrombocytopenic Purpura (ITP) Based on National Health Registry Systems in Denmark, Sweden and Norway (20070797)
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in SwEden (OSCAR-SE)
Pan European Multi-Database Bladder Cancer Risk Characterisation Study
PaTernal exposure to vAlproate, further iNvestiGation on the risk of NeuroDevelopmental Disorders (NDD) and Major Congenital Malformation (MCM) in Offspring: A Non-Interventional Post-Authorization Safety Study (TANGO)
Pharmacoepidemiological study (Drug Utilization Study) of JAYDESS use in routine clinical practice in Sweden (Jaydess DUS)
POST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN SWEDEN
POST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN THE NETHERLANDS
Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury
Post-authorization Safety Program Using the Swedish National Registers—A Validation Study of Cardiovascular and Neoplasm Events in Users of PharmacologicalTreatments for Overactive Bladder
Post-authorization Safety Study Evaluation of Cardiovascular Events in Users of Mirabegron and Other Treatments for Overactive Bladder
Post-authorization Safety Study Evaluation of Neoplasm Events in Users of Mirabegron and Other Treatments for Overactive Bladder : Core Common Protocol
Postauthorisation Safety Study (PASS) of Avatrombopag and Haematological Malignancies in Patients With Primary Immune Thrombocytopaenia
Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids (JOELLE)
Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids: Protopic JOint European Longitudinal Lymphoma and skin cancer Evaluation (JOELLE) Study
RRA-17425, Risperidone Exposure and the Risk of Osteoporosis-related Fractures – Sweden
Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases
Use of Bone Marrow Biopsies in Patients With Chronic Immune Thrombocytopenia: Predictors For, And Prognosis After – a Nordic Population-based Cohort Study And a Nested Case Control Study